Advertisement
PUNE, India, Nov. 10, 2016 /PRNewswire-iReach/ -- The global gout therapeutics market analyst says the use of regenerative medicine is an emerging treatment option for the treatment of gout. These regenerative medicines help in the healing process by replacement or regeneration of the human cells, tissues or organs, and thus help in establishing the normal function. The various regenerative techniques include cell therapy, growth factor therapy, and others.
(Photo - http://photos.prnewswire.com/prnh/20161110/437760)
Complete report on gout therapeutics market spread across 59 pages, analysing 3 major companies and providing 57 data exhibits is now available at http://www.reportsnreports.com/reports/738716-global-gout-therapeutics-market-2016-2020.html
The following companies are the key players in the global gout therapeutics market: AstraZeneca, Horizon Pharma, and Takeda Pharmaceuticals. Other prominent vendors in the market are: Ablynx, Alder Biopharmaceuticals, Antares Pharma, Astellas Pharma, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celltrion, ChemoCentryx, CymaBay Therapeutics, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Incyte, Ironwood Pharmaceuticals, JW Pharmaceutical, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, Merck, Morphotek, Novartis, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz, Sanofi, Santarus, Selecta Biosciences, Teijin Pharma, UCB, and Vertex Pharmaceuticals.
According to the gout therapeutics market report, introduction of novel urate-lowering agents will drive growth in this market. Urate-lowering agents are increasingly becoming the preferred choice of treatment for gout, which will be used as add-on therapy to the existing standard of care and target the gout patients who failed the previous treatment. Order a copy of Global Gout Therapeutics Market 2016-2020 report @ http://www.reportsnreports.com/purchase.aspx?name=738716
Global Gout Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of gout and the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs.
EMEA accounted for around 28% of the global gout therapeutics market in 2015. The key revenue generators of the EMEA are the UK, Germany, France, Italy, and Spain. Due to the high prevalence rates of gout. APAC accounted for around 23% of the global gout therapeutics market and despite contributing the least among all regions; it is anticipated to witness highest growth during the forecast period. The market growth in APAC is mostly driven by the older population, demographic transition, increased awareness among people, and the rise in healthcare expenditure.
According to gout therapeutics market study, the non-steroidal anti-inflammatory drugs (NSAIDs) segment will dominate this market during the forecast period. Non-opioid analgesics are commonly used medications due to their efficacy antipyretic, analgesic, and anti-inflammatory actions. The inhibition of the cyclooxygenase enzyme due to blocking of the formation of prostaglandins in the peripheral tissues by NSAIDs reduces the pain at the site of the injury.
Further, the gout therapeutics market report states that the use of CAM for the treatment of gout is one challenge, which is expected to be increase during the forecast period. The National Arthritis Foundation reveals that more than one-third of gout arthritis patients in the US prefer CAM therapies.
About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Media Contact: Ritesh Tiwari, ReportsnReports, + 1 888 391 5441, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE ReportsnReports
Advertisement
(Photo - http://photos.prnewswire.com/prnh/20161110/437760)
Complete report on gout therapeutics market spread across 59 pages, analysing 3 major companies and providing 57 data exhibits is now available at http://www.reportsnreports.com/reports/738716-global-gout-therapeutics-market-2016-2020.html
The following companies are the key players in the global gout therapeutics market: AstraZeneca, Horizon Pharma, and Takeda Pharmaceuticals. Other prominent vendors in the market are: Ablynx, Alder Biopharmaceuticals, Antares Pharma, Astellas Pharma, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celltrion, ChemoCentryx, CymaBay Therapeutics, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Incyte, Ironwood Pharmaceuticals, JW Pharmaceutical, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, Merck, Morphotek, Novartis, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz, Sanofi, Santarus, Selecta Biosciences, Teijin Pharma, UCB, and Vertex Pharmaceuticals.
According to the gout therapeutics market report, introduction of novel urate-lowering agents will drive growth in this market. Urate-lowering agents are increasingly becoming the preferred choice of treatment for gout, which will be used as add-on therapy to the existing standard of care and target the gout patients who failed the previous treatment. Order a copy of Global Gout Therapeutics Market 2016-2020 report @ http://www.reportsnreports.com/purchase.aspx?name=738716
Global Gout Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of gout and the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs.
EMEA accounted for around 28% of the global gout therapeutics market in 2015. The key revenue generators of the EMEA are the UK, Germany, France, Italy, and Spain. Due to the high prevalence rates of gout. APAC accounted for around 23% of the global gout therapeutics market and despite contributing the least among all regions; it is anticipated to witness highest growth during the forecast period. The market growth in APAC is mostly driven by the older population, demographic transition, increased awareness among people, and the rise in healthcare expenditure.
According to gout therapeutics market study, the non-steroidal anti-inflammatory drugs (NSAIDs) segment will dominate this market during the forecast period. Non-opioid analgesics are commonly used medications due to their efficacy antipyretic, analgesic, and anti-inflammatory actions. The inhibition of the cyclooxygenase enzyme due to blocking of the formation of prostaglandins in the peripheral tissues by NSAIDs reduces the pain at the site of the injury.
Further, the gout therapeutics market report states that the use of CAM for the treatment of gout is one challenge, which is expected to be increase during the forecast period. The National Arthritis Foundation reveals that more than one-third of gout arthritis patients in the US prefer CAM therapies.
About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Media Contact: Ritesh Tiwari, ReportsnReports, + 1 888 391 5441, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE ReportsnReports
